Michael J. Mauro
0000-0002-2251-4032
Publication & Citation Trends
Most Cited Works
Publications
466 total
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials OA
Cited by 29
Semantic Scholar
CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib OA
Cited by 0
Semantic Scholar
A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Cited by 0
Semantic Scholar
Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib OA
Cited by 8
Semantic Scholar
ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).
Cited by 1
Semantic Scholar
POSTER: CML-398 Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study OA
Cited by 0
Semantic Scholar
CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial OA
Cited by 0
Semantic Scholar
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial OA
Cited by 16
Semantic Scholar
Research Topics
Chronic Myeloid Leukemia Treatments
(404)
Chronic Lymphocytic Leukemia Research
(289)
Eosinophilic Disorders and Syndromes
(115)
Acute Lymphoblastic Leukemia research
(69)
Click Chemistry and Applications
(46)
Frequent Co-Authors
Affiliations
Novartis (Switzerland)
University Medical Center Groningen
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Inserm